NEW YORK, Dec. 21 - Gene Logic has struck a new partnership with Pfizer to co-develop a toxicogenomics database to screen the drug giant's compound library, Gene Logic said on Friday.
The informatics and content provider also said Pfizer has licensed its Genesis GeneExpress platform, signalling an extension of a deal previously penned by the two firms.
Financial terms of the deals were not disclosed.
The database development agreement, called the Predictive Toxicology Program, builds on Pfizer's current subscription to Gene Logic's ToxExpress Module for which Pfizer will provide compound samples that will be tested to determine their safety profiles, according to Gene Logic.
Data gleaned from this exercise might then be integrated with the other data sets used by Pfizer, said Gene Logic, "thereby creating a single information resource to further enable Pfizer's toxicogenomics efforts."
Under the terms of the Genesis licensing agreement, meanwhile, researchers at Pfizer will be given access to the software for a broad range of uses, and will employ the system to help integrate its own data with GeneExpress data.
In October, Pfizer had extended to five years its subscription to Gene Logic's ToxExpress database module after the two firms announced in January plans to co-develop a microarray for toxicology studies that would use Affymetrix's GeneChip technology.
Under that agreement, researchers at Gene Logic and Pfizer said they would design the array and Affymetrix would build it. The array will only be available to subscribers of Gene Logic's ToxExpress and is designed to complement the ToxExpress' library of toxicity markers.
ToxExpress is a module in the GeneExpress suite of databases. It offers data on the effects of more than 10 toxic compounds on the liver, kidney, bone marrow, and heart of animals.